NEW YORK CITY, NY / ACCESS Newswire / November 11, 2026 / Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) disclosed on November 9, 2026 that TRYNGOLZA's launch in severe hypertriglyceridemia (sHTG) is ramping "more gradually than expected." IONS shares fell sharply as third-quarter sales of the drug dropped roughly 71% from the prior-year quarter. If you bought IONS and are now looking at losses, you may have legal rights. Affected shareholders are encouraged to start a confidential loss review now or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

The FDA approved TRYNGOLZA (olezarsen) in December 2024 for familial chylomicronemia syndrome, a rare genetic disorder. Ionis launched TRYNGOLZA in sHTG, a substantially larger patient population, in 2026. Ionis has projected more than $3 billion in peak annual revenue for TRYNGOLZA.

Third-quarter 2026 TRYNGOLZA product sales were approximately $9.3 million, compared with roughly $31.8 million in the third quarter of 2025. Second-quarter 2026 sales were $5 million. Ionis now expects roughly $50 million in full-year 2026 TRYNGOLZA product sales, down from their previous guidance for "$100-110 million." Levi & Korsinsky is investigating potential securities law violations on behalf of IONS investors.

If your IONS position lost value after the sHTG launch update, find out whether you can recover your losses or call (212) 363-7500.

WHY LEVI & KORSINSKY -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered billions of dollars for investors.

Frequently Asked Questions About the IONS Investigation

Q: Who is eligible to participate in the IONS investigation? A: Investors who purchased IONS stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Ionis Pharmaceuticals, Inc. made materially false or misleading statements regarding the commercial outlook for TRYNGOLZA, including its launch in severe hypertriglyceridemia. When the Company disclosed on November 9, 2026 that the sHTG launch was ramping more gradually than expected and lowered its 2026 TRYNGOLZA product sales guidance, the stock price declined sharply.

Q: When did Ionis Pharmaceuticals allegedly mislead investors? A: The investigation concerns statements made before the corrective disclosure that allegedly caused investors to purchase securities at inflated prices.

Q: What do IONS investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What is a lead plaintiff and why does it matter? A: If the investigation proceeds to legal action, a lead plaintiff is the investor the court appoints to represent the group of affected investors. Lead plaintiffs are typically investors with the largest documented losses. Contacting the firm during the investigation phase preserves that option.

Q: What if I already sold my IONS shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought IONS and sold at a loss may still participate in the investigation.

Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.

Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

SOURCE: Levi & Korsinsky, LLP